Carlo R.
- Country
- Italy
- Department
- Medical Oncology and Hematology Unit
Research Overview
- Phase II Open-Label Single-Arm Multicentre Study of Cemiplimab for Organ Preservation in Locally Advanced Cutaneous Squamous Cell Carcinoma (INCEPT)
- Phase II Evaluation of Cetuximab, Platinum, and Taxane-Based Chemotherapy Followed by Avelumab and Cetuximab in PD-L1 CPS ≥1 Recurrent/Metastatic HNSCC
- Phase II Evaluation of Sonidegib in Nevoid Basal Cell Carcinoma Syndrome and Sporadic Basal Cell Carcinoma Patients in EADO Stage IIb
Data & Insights
Has run more than one trial at 11 of 23 partner sites.
Specializations
Dermatological Oncology
The investigator specializes in the treatment of Nevoid Basal Cell Carcinoma Syndrome, also known as Gorlin syndrome, and demonstrates particular expertise in managing basal cell carcinoma conditions.
- Advanced BCC Management
- Genetic Skin Disorders
- Targeted Therapy Approaches
Their research extends to the evaluation of therapeutic interventions for both hereditary and sporadic forms of BCC.
Precision Medicine
The investigator focuses on developing personalized treatment strategies for patients with advanced skin cancers, particularly exploring innovative dosing schedules and treatment protocols.
- Treatment Optimization
- Long-term Management
- Patient Compliance Studies
Their work encompasses the study of treatment adherence and therapeutic effectiveness in complex dermatological conditions.
Genetic Syndromes
The investigator specializes in the study of hereditary cancer syndromes, with particular attention to dermatological manifestations and their clinical management.
- Inherited Cancer Predisposition
- Syndrome-specific Interventions
- Clinical Outcomes Assessment
Their expertise includes the evaluation of targeted therapies for genetically-driven skin cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.